# Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer

> **NCT00191243** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 237 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00191243
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2007-08
- **Final completion:** 2009-04
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191243, "Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00191243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*